GT
GILD icon

Glenmede Trust’s Gilead Sciences GILD Stock Holding History

Glenmede Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$2K – 1216
2020
Q4 		$2K Buy
+20
New +$1.21K ﹤0.01% 1183

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Glenmede Trust's GILD Position: Q2 2026 in Review

Glenmede Trust reduced its Gilead Sciences (GILD) stake by 10% in Q2 2026, selling an estimated $2.93M and leaving 199,749 shares worth $25.2M. The position accounts for 0.11% of the portfolio, ranked #153.

Glenmede Trust first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $94M in Q2 2016. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Glenmede Trust held 199,749 shares of Gilead Sciences worth $25.2M as of Q2 2026.
  • Glenmede Trust sold 22,226 Gilead Sciences shares in Q2 2026, an estimated $2.93M.
  • Gilead Sciences made up 0.11% of Glenmede Trust's portfolio in Q2 2026, its #153 holding.
  • Glenmede Trust first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • Glenmede Trust's Gilead Sciences position peaked at $94M in Q2 2016.
  • 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.